COBLL1 Antibody

Key Antibody Providers

Western Blot (WB)

COBLL1 antibodies are used to analyze protein expression in cell lysates and tissues. For example:

• Prostate Cancer Models: Detected COBLL1 upregulation in castration-resistant prostate cancer (CRPC) cells (LTAD, 22Rv1) and its role in AR phosphorylation (Ser81) and nuclear localization .

• Leukemia Studies: Identified COBLL1 as a biomarker in chronic lymphocytic leukemia (CLL), correlating with poor prognosis in unmutated IGHV subgroups .

Immunohistochemistry (IHC)

• Prostate Cancer Tissues: Demonstrated cytoplasmic and nuclear COBLL1 expression, with high levels linked to poor survival and high Gleason scores .

• Mouse Kidney/Placenta: Validated using antigen retrieval (TE buffer pH 9.0 or citrate buffer pH 6.0) .

Immunofluorescence (IF/ICC)

• Cell Morphology: Revealed COBLL1’s colocalization with F-actin in CRPC cells, showing neuron-like extensions (dendrites) and actin bundle formation .

• Nuclear Localization: Detected COBLL1 in the nucleus of prostate cancer cells, interacting with CDK1 and AR .

Prostate Cancer

Chronic Lymphocytic Leukemia (CLL)

Western Blot Protocol

1. Sample Preparation: Lyse cells in RIPA buffer; resolve proteins via SDS-PAGE.

2. Transfer: Transfer to PVDF membrane; block with 5% BSA/TBST.

3. Primary Antibody: Incubate with COBLL1 antibody (1:1000–1:5000) overnight at 4°C.

4. Detection: Use HRP-conjugated secondary antibody and ECL reagent .

Immunohistochemistry Protocol

1. Antigen Retrieval: Heat with TE buffer (pH 9.0) or citrate buffer (pH 6.0).

2. Staining: Block with 10% goat serum; apply COBLL1 antibody (1:50–1:500) for 1 hour.

3. Detection: Use HRP-conjugated secondary and DAB substrate .

Prognostic and Diagnostic Relevance

COBLL1 antibodies enable biomarker discovery in cancers:

• Prostate Cancer: High nuclear/cytoplasmic COBLL1 expression is an independent predictor of poor survival .

• CLL: COBLL1-high unmutated IGHV CLL patients show impaired chemotaxis and aggressive disease .

Limitations and Considerations

• Cross-Reactivity: Verify specificity in non-human samples (e.g., mouse/rat) .

• Tissue Fixation: Optimize fixation protocols for IHC (e.g., formalin) .

• Batch Variability: Titrate antibodies for each experiment .